ARWR - Arrowhead Pharmaceuticals Stock Price, News & Analysis

$3.63 -0.06 (-1.63 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$3.69
Today's Range$3.61 - $3.73
52-Week Range$1.20 - $4.70
Volume371,200 shs
Average Volume953,415 shs
Market Capitalization$272.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86

About Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:ARWR
  • CUSIP: N/A
  • Web: arrowheadpharma.com
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 3.84%
  • Quick Ratio: 3.84%
Sales & Book Value:
  • Annual Sales: $160,000.00
  • Price / Sales: 1,696.34
  • Book Value: $1.56 per share
  • Price / Book: 2.33
Profitability:
  • Trailing EPS: ($0.67)
  • Net Income: $-81,720,000.00
  • Net Margins: -201.84%
  • Return on Equity: -46.73%
  • Return on Assets: -34.08%
Misc:
  • Employees: 94
  • Outstanding Shares: 74,770,000
 

Frequently Asked Questions for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. The biotechnology company had revenue of $39.58 million for the quarter, compared to analysts' expectations of $0.05 million. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The business's revenue for the quarter was down 68.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.27) EPS. View Arrowhead Pharmaceuticals' Earnings History.

When will Arrowhead Pharmaceuticals make its next earnings announcement?

Arrowhead Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Arrowhead Pharmaceuticals.

Where is Arrowhead Pharmaceuticals' stock going? Where will Arrowhead Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1 year target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Arrowhead Pharmaceuticals' stock price to reach $2.00 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.

Who are some of Arrowhead Pharmaceuticals' key competitors?

Who are Arrowhead Pharmaceuticals' key executives?

Arrowhead Pharmaceuticals' management team includes the folowing people:

  • Douglass B. Given M.D., Ph.D., Chairman of the Board (Age 64)
  • Christopher Richard Anzalone Ph.D., President, Chief Executive Officer, Director (Age 47)
  • Kenneth Allen Myszkowski, Chief Financial Officer (Age 50)
  • Bruce D. Given M.D., Chief Operating Officer (Age 62)
  • Patrick O'Brien, General Counsel (Age 53)
  • Michael S. Perry Ph.D., Lead Independent Director (Age 57)
  • Mauro Ferrari Ph.D., Independent Director (Age 57)
  • Edward W. Frykman, Independent Director (Age 80)

Who owns Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include ING Groep NV (1.08%), Allianz Asset Management GmbH (0.60%), Schwab Charles Investment Management Inc. (0.23%) and Dimensional Fund Advisors LP (0.06%). Company insiders that own Arrowhead Pharmaceuticals stock include Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.

Who bought Arrowhead Pharmaceuticals stock? Who is buying Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including ING Groep NV, Allianz Asset Management GmbH, Dimensional Fund Advisors LP and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Arrowhead Pharmaceuticals.

How do I buy Arrowhead Pharmaceuticals stock?

Shares of Arrowhead Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arrowhead Pharmaceuticals' stock price today?

One share of Arrowhead Pharmaceuticals stock can currently be purchased for approximately $3.63.

How big of a company is Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has a market capitalization of $272.17 million and generates $160,000.00 in revenue each year. The biotechnology company earns $-81,720,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. Arrowhead Pharmaceuticals employs 94 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 225 S Lake Ave Ste 1050, PASADENA, CA 91101-4820, United States. The biotechnology company can be reached via phone at +1-626-3043400 or via email at [email protected]


MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $2.00 (44.90% downside)

Consensus Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Price Target History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Analysts' Ratings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/25/2017Cantor FitzgeraldReiterated RatingHold$2.00MediumView Rating Details
9/18/2017William BlairUpgradeMarket Perform -> OutperformHighView Rating Details
9/13/2017Chardan CapitalReiterated RatingNeutralMediumView Rating Details
8/4/2017Jefferies Group LLCReiterated RatingHold$2.00HighView Rating Details
7/28/2017Piper Jaffray CompaniesReiterated RatingHold$2.00MediumView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Earnings by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Earnings History by Quarter for Arrowhead Pharmaceuticals (NASDAQ ARWR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017($0.10)N/AView Earnings Details
8/3/2017Q3 2017($0.13)($0.07)$5.29 million$9.34 millionViewListenView Earnings Details
5/3/2017Q2 2017($0.12)($0.08)$4.19 million$8.99 millionViewListenView Earnings Details
2/6/2017Q117($0.20)($0.17)$13.24 million$4.37 millionViewListenView Earnings Details
8/9/2016Q316($0.37)($0.32)$0.05 million$39.58 millionViewN/AView Earnings Details
5/10/2016Q216($0.37)($0.35)$0.26 million$0.04 millionViewListenView Earnings Details
2/9/2016Q1($0.41)($0.32)$0.29 million$0.04 millionViewN/AView Earnings Details
12/14/2015Q415($0.39)($0.42)$0.14 million$0.04 millionViewListenView Earnings Details
8/4/2015Q315($0.38)($0.27)$0.11 million$0.12 millionViewN/AView Earnings Details
5/11/2015Q214($0.35)($0.33)$110.00 million$43.75 millionViewListenView Earnings Details
2/9/2015Q114($0.32)($0.41)$0.24 million$0.17 millionViewN/AView Earnings Details
11/25/2014Q413($0.25)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
8/12/2014Q313($0.22)($0.22)$0.04 million$0.04 millionViewN/AView Earnings Details
5/6/2014Q2 2014($0.18)($0.31)$0.05 million$0.04 millionViewN/AView Earnings Details
2/4/2014Q4($0.18)($0.33)ViewN/AView Earnings Details
12/18/2013Q4($0.23)($0.43)ViewListenView Earnings Details
5/9/2013Q2 2013($0.41)ViewN/AView Earnings Details
2/13/2013Q1 2013($0.33)ViewN/AView Earnings Details
12/20/2012Q4 2012($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
2017 EPS Consensus Estimate: ($0.21)
2018 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.22$0.22$0.22
Q2 20172($0.16)($0.11)($0.14)
Q3 20173($0.15)($0.13)($0.14)
Q4 20173($0.18)($0.10)($0.15)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Insider Ownership Percentage: 4.57%
Institutional Ownership Percentage: 21.44%
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Insider Trades by Quarter for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/14/2016Douglas B. GivenDirectorSell12,000$6.72$80,640.00View SEC Filing  
8/23/2016Kenneth Allen MyszkowskiCFOSell6,900$8.00$55,200.00View SEC Filing  
8/22/2016Kenneth Allen MyszkowskiCFOSell13,100$8.00$104,800.00View SEC Filing  
12/30/2015Kenneth Allen MyszkowskiCFOSell23,347$6.13$143,117.11View SEC Filing  
10/28/2015Mauro FerrariDirectorBuy400$7.62$3,048.00View SEC Filing  
10/9/2015Mauro FerrariDirectorBuy1,900$6.19$11,761.00View SEC Filing  
1/5/2015David L LewisInsiderSell15,000$8.01$120,150.00View SEC Filing  
10/15/2014Christopher Richard AnzaloneCEOBuy16,000$6.32$101,120.00View SEC Filing  
10/1/2014Charles MckenneyDirectorSell2,500$14.70$36,750.00View SEC Filing  
9/30/2014David L LewisInsiderSell15,000$15.02$225,300.00View SEC Filing  
9/26/2014Douglas B GivenDirectorSell2,000$15.24$30,480.00View SEC Filing  
6/9/2014Charles MckenneyDirectorSell22,000$14.32$315,040.00View SEC Filing  
2/12/2014Kenneth Allen MyszkowskiCFOSell16,000$18.77$300,320.00View SEC Filing  
2/7/2014Edward W FrykmanDirectorSell3,148$15.98$50,305.04View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arrowhead Pharmaceuticals (NASDAQ ARWR)

Source:
DateHeadline
Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference - Business Wire (press release)Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 15 at 2:39 AM
Arrowhead to Present at 29th Annual Piper Jaffray Healthcare ConferenceArrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 14 at 4:35 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Expected to Announce Quarterly Sales of $7.32 MillionArrowhead Pharmaceuticals, Inc. (ARWR) Expected to Announce Quarterly Sales of $7.32 Million
www.americanbankingnews.com - November 11 at 10:02 AM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 3, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 3, 2017
finance.yahoo.com - November 3 at 4:26 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Rating of "Hold" from BrokeragesArrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 2 at 3:32 AM
Financial Comparison: Arrowhead Pharmaceuticals (ARWR) vs. Its CompetitorsFinancial Comparison: Arrowhead Pharmaceuticals (ARWR) vs. Its Competitors
www.americanbankingnews.com - October 30 at 5:26 PM
Arrowhead Pharmaceuticals Corp (ARWR) Reports Promising ... - StreetInsider.comArrowhead Pharmaceuticals Corp (ARWR) Reports Promising ... - StreetInsider.com
www.streetinsider.com - October 23 at 10:09 PM
Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017
finance.yahoo.com - October 23 at 5:07 PM
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
finance.yahoo.com - October 23 at 5:07 PM
Contrasting Sarepta Therapeutics (SRPT) and Arrowhead Pharmaceuticals (ARWR)Contrasting Sarepta Therapeutics (SRPT) and Arrowhead Pharmaceuticals (ARWR)
www.americanbankingnews.com - October 21 at 4:24 AM
Arrowhead Pharmaceuticals (ARWR) & The Competition Financial SurveyArrowhead Pharmaceuticals (ARWR) & The Competition Financial Survey
www.americanbankingnews.com - October 21 at 4:24 AM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 16, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 4:52 PM
Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting®
finance.yahoo.com - October 10 at 5:25 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by BrokeragesArrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 8 at 4:50 AM
Arrowhead to Present at Chardan Gene Therapy ConferenceArrowhead to Present at Chardan Gene Therapy Conference
finance.yahoo.com - October 4 at 2:07 PM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 2, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 3:56 PM
Arrowhead Data Reveal Important Considerations for Future Hepatitis B TreatmentArrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
www.businesswire.com - September 27 at 7:55 PM
Arrowhead Pharmaceuticals (ARWR) "Hold" Rating Reiterated at Cantor FitzgeraldArrowhead Pharmaceuticals' (ARWR) "Hold" Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 11:38 AM
Arrowhead Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.11) Per Share, William Blair Forecasts (ARWR)Arrowhead Pharmaceuticals, Inc. to Post Q1 2018 Earnings of ($0.11) Per Share, William Blair Forecasts (ARWR)
www.americanbankingnews.com - September 20 at 9:22 AM
Arrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Outperform at William BlairArrowhead Pharmaceuticals, Inc. (ARWR) Lifted to Outperform at William Blair
www.americanbankingnews.com - September 18 at 11:32 PM
Analyzing Arrowhead Pharmaceuticals (ARWR) and BioCryst Pharmaceuticals (BCRX)Analyzing Arrowhead Pharmaceuticals (ARWR) and BioCryst Pharmaceuticals (BCRX)
www.americanbankingnews.com - September 17 at 2:31 AM
Arrowhead Pharmaceuticals, Inc. (ARWR) Receives "Neutral" Rating from Chardan CapitalArrowhead Pharmaceuticals, Inc. (ARWR) Receives "Neutral" Rating from Chardan Capital
www.americanbankingnews.com - September 16 at 7:18 AM
Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike TodayHere's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today
finance.yahoo.com - September 15 at 4:23 PM
Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)Cantor Fitzgerald Reaffirms Hold Rating for Arrowhead Pharmaceuticals, Inc. (ARWR)
www.americanbankingnews.com - September 15 at 7:28 AM
Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug CandidatesArrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM™ Platform and Lead RNAi-based Drug Candidates
finance.yahoo.com - September 14 at 4:38 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by AnalystsArrowhead Pharmaceuticals, Inc. (ARWR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 13 at 5:06 AM
ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017
finance.yahoo.com - September 12 at 2:00 AM
Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare ConferenceArrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 11 at 8:58 PM
Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017
finance.yahoo.com - September 8 at 10:05 PM
Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies - Business Wire (press release)Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies - Business Wire (press release)
www.businesswire.com - September 1 at 9:40 PM
Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based TherapiesArrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies
finance.yahoo.com - September 1 at 4:37 PM
FY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lifted by Analyst (ARWR)FY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Lifted by Analyst (ARWR)
www.americanbankingnews.com - August 28 at 3:38 AM
$7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter$7.32 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (ARWR) This Quarter
www.americanbankingnews.com - August 27 at 5:50 AM
Contrasting Arrowhead Pharmaceuticals (ARWR) and Biopharmx Corp (BPMX)Contrasting Arrowhead Pharmaceuticals (ARWR) and Biopharmx Corp (BPMX)
www.americanbankingnews.com - August 19 at 8:44 AM
Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Average Rating of "Hold" from BrokeragesArrowhead Pharmaceuticals, Inc. (ARWR) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 19 at 4:36 AM
Financial Comparison: Arrowhead Pharmaceuticals (ARWR) and Aldeyra Therapeutics (ALDX)Financial Comparison: Arrowhead Pharmaceuticals (ARWR) and Aldeyra Therapeutics (ALDX)
www.americanbankingnews.com - August 16 at 4:58 PM
$7.98 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter$7.98 Million in Sales Expected for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) This Quarter
www.americanbankingnews.com - August 9 at 7:46 AM
Today’s Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead PharmaceuticalsToday’s Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead Pharmaceuticals
finance.yahoo.com - August 8 at 3:56 PM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given "Hold" Rating at Jefferies Group LLCArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given "Hold" Rating at Jefferies Group LLC
www.americanbankingnews.com - August 6 at 12:34 AM
Arrowhead Pharmaceuticals (ARWR) CEO Christopher Anzalone on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 9:24 PM
Edited Transcript of ARWR earnings conference call or presentation 3-Aug-17 8:30pm GMTEdited Transcript of ARWR earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 4:22 PM
Arrowhead Pharmaceuticals, Inc. (ARWR) Announces  Earnings ResultsArrowhead Pharmaceuticals, Inc. (ARWR) Announces Earnings Results
www.americanbankingnews.com - August 4 at 4:20 PM
Investor Network: Arrowhead Pharmaceuticals, Inc. to Host Earnings CallInvestor Network: Arrowhead Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 5:29 PM
Arrowhead Reports Fiscal 2017 Third Quarter ResultsArrowhead Reports Fiscal 2017 Third Quarter Results
finance.yahoo.com - August 3 at 5:29 PM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Scheduled to Post Earnings on MondayArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:20 AM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earns Hold Rating from Piper Jaffray CompaniesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Earns Hold Rating from Piper Jaffray Companies
www.americanbankingnews.com - July 30 at 3:56 PM
Popular biotech ETF on pace for steepest daily drop in a month - MarketWatchPopular biotech ETF on pace for steepest daily drop in a month - MarketWatch
www.marketwatch.com - July 27 at 4:07 PM
Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter ResultsArrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results
finance.yahoo.com - July 27 at 4:06 PM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Hold" from AnalystsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 25 at 10:27 AM
 Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Announce Earnings of -$0.13 Per Share Analysts Expect Arrowhead Pharmaceuticals, Inc. (ARWR) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 18 at 12:22 AM

Social Media

Financials

Chart

Arrowhead Pharmaceuticals (NASDAQ ARWR) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.